Cardio Diagnostics Holdings, Inc.
Moat Score — Cardio Diagnostics Holdings, Inc.
Total Moat Score
5 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 3 / 5 | Cardio Diagnostics holds seven patent families, including two issued U.S. patents and international patents across ten countries, plus an exclusive license from the University of Iowa Research Foundation on core epigenetic-biomarker IP expiring in 2037/2041 - a genuine and durable technical moat, though still largely unmonetized. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 0 / 5 | As a pre-revenue-scale company (roughly $14,450 TTM revenue) running its own new CLIA lab, Cardio Diagnostics has no demonstrated cost advantage and is still absorbing the fixed costs of standing up laboratory operations. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 1 / 5 | The company depends on a CMS gapfill payment rate of $854 per test that it did not set and that could change, and its own filing warns that securing broad payer coverage "could take years," leaving essentially no independent pricing power today. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | Diagnostic blood testing carries no network effect; a patient's or physician's use of Cardio's tests does not become more valuable as more patients or physicians use them. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 1 / 5 | The company's strategy of signing exclusivity agreements with health systems, concierge practices and telemedicine channels could eventually create real switching costs once adopted, but with minimal current revenue and long (up to 24-month) sales cycles this advantage remains largely aspirational. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 0 / 5 | The cardiovascular risk-testing market includes numerous well-resourced alternatives (lipid calculators, imaging, proteomic tests, larger genetic testing firms), and Cardio Diagnostics itself acknowledges competitors with far greater financial and research resources, leaving no efficient-scale protection at its current size. |